New hope for Hard-to-Treat breast cancer? early trial of AC699 begins
Disease control
Ongoing
This early-phase study tests a new drug, AC699, in about 100 people with a common type of advanced breast cancer (ER+/HER2-). The main goal is to find a safe dose and check for side effects. Researchers will also see if the drug can shrink tumors. Participants must have tried oth…
Phase: PHASE1 • Sponsor: Accutar Biotechnology Inc • Aim: Disease control
Last updated May 08, 2026 12:00 UTC